Sign In
to Vote &
Create Storyboards.
 
For the subset of women with BRCA mutations who have already had ovarian cancer, risk-reducing mastectomy might not be worth the price tag. New research finds that for many women in this unique group, prophylactic mastectomy does not produce a substantial survival gain compared to breast cancer screening and is not cost-effective.
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard